A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease (BeyoND)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02726386|
Recruitment Status : Active, not recruiting
First Posted : April 1, 2016
Results First Posted : May 6, 2023
Last Update Posted : May 6, 2023
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Parkinson's Disease||Drug: ND0612||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||214 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease|
|Actual Study Start Date :||May 2016|
|Actual Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||February 2027|
Experimental: 24-hour dosing regimen
Continuous SC infusion over 24 hours: fixed day rate of up to 0.64 mL/h for 18 hours, followed by a night rate of 0.08 mL/h for 6 hours to deliver a total daily dose of up to 720/90 mg of levodopa/carbidopa.
All patients who had been previously assigned to the 24-hour group in the prior study continued on this dosing regimen; patients who had previously been assigned to the 14-hour daytime regimen were switched to the 24-hour regimen.
ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
Other Name: ND0612H
Experimental: 16-hour dosing regimen
Continuous SC infusion for over 16 hours: fixed rate of 0.75 mL/h to deliver a total infusion dose of 720/90 mg of levodopa/carbidopa over 16 hours.
The device is removed at night and patients in this group also receive a morning oral dose of levodopa/carbidopa upon awakening.
ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
Other Name: ND0612H
- Adverse Events (Long-term Safety) [ Time Frame: Baseline to Month 12 ]Long-term safety (systemic and local) assessment will be based on adverse events (AEs), with a focus on adverse events of special interest (AESI), i.e., infusion site reactions, cases of hypersensitivity, polyneuropathy.
- Percentages of Subjects Who Complete the 12-month Treatment Period or Discontinue Due to AE (Tolerability) [ Time Frame: Baseline to Month 12 ]Tolerability will be assessed based on the percentage of subjects that complete the 12-month treatment period of the study and the percentage of subjects who discontinue from the 12-month treatment period due to an AE.
- Adverse Events (Long-term Safety) [ Time Frame: Month 12 to Month 102 ]Long-term safety (systemic and local) and tolerability will be based on AEs, with a focus on AESI, i.e., infusion site reactions, cases of hypersensitivity, polyneuropathy.
- Change of Daily "ON" Time Without Troublesome Dyskinesia [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. "ON" time without troublesome dyskinesia is defined as the sum of "ON" time without dyskinesia and "ON" time with non-troublesome dyskinesia. Daily "ON" time without troublesome dyskinesia will be assessed based on home "ON/OFF" diaries and normalized to 16 hours of awake time.
- Change of Daily "OFF" Time [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. Daily "OFF" time will be assessed based on home "ON/OFF" diaries and normalized to 16 hours of awake time.
- Change of Total Daily Dose of Oral LD/DDI [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. Total daily dose of oral Levodopa (LD)/Dopa-Decarboxylase Inhibitor (DDI).
- Proportion of Responders [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. A responder is defined as a subject that experiences ≥50% reduction in "OFF" time from Baseline. Improvement of ≥50% in "OFF" time will be assessed based on home "ON/OFF" diaries and normalized to 16 hours of awake time.
- Change of Daily "ON" Time With Troublesome Dyskinesia [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. Daily "ON" time with troublesome dyskinesia will be assessed based on home "ON/OFF" diaries in a subset of subjects who had more than 1 hour of troublesome dyskinesia at baseline. It will be normalized to 16 hours of awake time.
- Change of PDQ-39 Scores [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. Quality of Life in Parkinson's Disease (PDQ)-39 is a 39-item, self-administered questionnaire with 8 discrete dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort.). The PDQ-39 Summary Index is the sum of the dimension scores divided by the number of dimensions. Higher scores indicate a worse quality of life.
- Change of EQ-5D-5L Scores [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. The perception of general quality of life (QoL) will be rated by the subjects using the EuroQoL 5-dimensions 5-severity levels (EQ-5D-5L) questionnaire. The EQ-5D-5L consists of 2 pages, the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. Decrease in the 5-dimensions scores and increase in EQ VAS score will indicate improvement.
- Change of UPDRS Part II (ADL) [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. The Unified Parkinson's disease rating scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS Part II (activity of daily living) score was calculated as the sum of the individual UPDRS items 5-17. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (i.e., 0 is normal and 4 indicates a severe abnormality). Higher scores correlate with greater impairments for daily activities.
- Change in CGI-Severity and CGI-Improvement [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. Clinical Global Impression (CGI) Severity (CGI-S) and Improvement (CGI-I) are rated by the investigator or designee. CGI-S employs a 7-point scale with 1 being "not at all ill" and 7 being "among the most severely ill subjects" for severity rating. The CGI-I employs a 7-point scale with 1 being "very much improved" and 7 being "very much worse" for improvement rating.
- Change in SGI-Improvement [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. Subjects Global Impression of Improvement (SGI-I) is rated by the subject. The SGI-I employs a 7-point scale with 1 being "very much improved" and 7 being "very much worse" for improvement rating.
- Change in PDSS-2 Total Score [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. The quality of night sleep is rated by the subjects using the Parkinson's Disease Sleep Scale (PDSS)-2, which includes questions addressing 15 commonly reported symptoms associated with sleep disturbance in PD. Higher scores indicate a lower quality of sleep, i.e., a reduction in the score indicates an improvement in sleep quality.
- Change in UPDRS Part III (Motor Score) [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. UPDRS part III (motor) score is calculated as the sum of the individual UPDRS items 18-31, each of which are measured on a 5-point scale (i.e., 0 is normal and 4 indicates a severe abnormality). Higher scores correlate with greater motor impairment.
- Change in Percentage of "OFF" Time and Percentage of Good "ON" During the First 3 Hours Since the Subject is Awake After 06:00 (6 am) [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. Good "ON" time (or "ON" time without troublesome dyskinesia) is defined as the sum of "ON" time without dyskinesia and "ON" time with non-troublesome dyskinesia. For this endpoint, Good "ON" time and "OFF" time will be assessed based on home "ON/OFF" diaries during the first 3 hours since the subject is awake after 06:00 (6 am).
- Change in ND0612 Total Dose [ Time Frame: Baseline to Month 12 ]Exploratory endpoint. Change in ND0612 total daily dose.
- Proportion of Patients Who Reduced ND0612 Total Dose [ Time Frame: Baseline to Month 102 ]Exploratory endpoint. Proportion of patients who reduced ND0612 total dose at any time during the study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||30 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Subject is able to, and has signed an Institutional Review Board/Ethics Committee (IRB/EC)-approved informed consent form (ICF).
- Subject has completed the treatment period of study ND0612H-006 not more than one month prior to enrolling in ND0612H-012.
- Willing and able to administer the SC infusion alone or with the assistance of a study partner and able to comply with the study specific procedures.
- Male and female PD subjects of any race aged at least 30 years who sign an IRB/EC-approved ICF.
- PD diagnosis consistent with the UK Brain Bank Criteria.
- Modified Hoehn & Yahr scale in "ON" state of stage ≤3.
- Taking at least 4 doses/day of LD/DDI (or at least 3 doses/day of Rytary) and taking, or have attempted to take, at least one other PD treatment for at least 30 days.
- Subjects must be stable on their anti-PD medications for at least 30 days before Day 1.
- Subjects may have had prior exposure to SC apomorphine injections/infusion but must have stopped continuous apomorphine administration at least 4 weeks before the screening visit. Treatment with apomorphine is prohibited during the entire ND0612 treatment period.
- Must have a minimum of 2 hrs of "OFF" time per day with predictable early morning "OFF" periods as estimated by the subject.
- Must have predictable and well defined early morning "OFF" periods with a good response to LD for treatment of the early morning "OFF" in the judgement of the investigator.
- Mini Mental State Examination (MMSE) score ≥26.
- No clinically significant medical, psychiatric or laboratory abnormalities which the investigator judges would be unsafe or non-compliant in the study.
- Female subjects must be surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation), postmenopausal (defined as cessation of menses for at least 1 year), or willing to practice a highly effective method of contraception. All female participants must be non-lactating and non-pregnant and have a negative urine pregnancy test at Screening and at Baseline. Female subjects of childbearing potential must practice a highly effective method of contraception (e.g., oral contraceptives, intrauterine devices, partner with vasectomy), 1 month before enrollment, for the duration of the study, and 3 months after the last dose of study drug. Alternatively, true abstinence is acceptable when it is in line with the subject's preferred and usual lifestyle. If a subject is usually not sexually active but becomes active, the subject and sexual partner must comply with the contraceptive requirements detailed above.
- Willing and able to administer the SC infusion alone or with the assistance of a study partner after a screening period of up to 40 days and willing and able to comply with study requirements.
- Subjects should have a named study partner.
Cohort 1 and 2. Previously unable to tolerate ND0612 and/or have experienced intolerable adverse drug reactions associated with its use, regardless of the dosing regimen administered.
- Atypical or secondary parkinsonism.
- Acute psychosis or hallucinations in past 6 months.
- Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
- Any malignancy in the 5 years prior to randomization (excluding basal cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated).
- Positive serum serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) at the Screening visit.
- Prior neurosurgical procedure for PD, or Duodopa treatment
- Subjects with a history of drug abuse or alcoholism within the past 12 months.
- Clinically significant ECG rhythm abnormalities.
- Renal or liver dysfunction that may alter drug metabolism including: serum creatinine >1.3 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x upper limit of normal (ULN), total serum bilirubin >2.5 mg/dL.
- Current participation in a clinical trial with an investigational product or past participation within the last 30 days before Day 1.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02726386
|Study Director:||Laurence Salin, MD||NeuroDerm Ltd.|
Documents provided by NeuroDerm Ltd.:
|Responsible Party:||NeuroDerm Ltd.|
|Other Study ID Numbers:||
|First Posted:||April 1, 2016 Key Record Dates|
|Results First Posted:||May 6, 2023|
|Last Update Posted:||May 6, 2023|
|Last Verified:||May 2023|
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases